RTW Venture Fund has provided a brief update on portfolio company Landos Biopharma’s IPO. The IPO raised US$100 million by offering 6,250,000 shares at $16.00 per share, and Landos is now listed on the Nasdaq Global Market under ticker: LABP. Landos was one of the seed assets included in the Company’s portfolio at the time of launch in October 2019 and, prior to IPO, RTW Venture Fund together with other funds managed by RTW Investments, LP co-led a $60 million Series B financing round in Landos in August 2019.
About Landos Biopharma
Landos is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oral therapeutics for patients with autoimmune diseases. Its lead asset BT-11 is a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway.
Comments from Stephanie Sirota, Chief Business Officer of the Investment Manager and Director of RTW Ventures
“We are pleased with Landos successfully going public via an IPO and look forward to remaining a reliable partner to the company post-IPO in its efforts to bring novel oral small molecule therapeutics for patients with autoimmune diseases.”
About RTW Venture Fund
RTW Venture Fund Limited is an investment fund that listed on the London Stock Exchange on 30 October 2019. It aims to identify transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. It is managed by RTW Investments, LP, a healthcare-focused investment firm with deep scientific expertise and a track record of supporting companies developing life-changing therapies. More information can be found at the company’s website: www.rtwfunds.com.